Marco Cippitelli

Full Professor of General Pathology and Immunology

marco.cippitelli@uniroma1.it

Academic Appointments

  • 1992-1995. Visiting Scientist at the “Biological Carcinogenesis and Development Program, ā€œMolecular Immunology Section” (Laboratory of Experimental Immunology) National Cancer Institute (NCI) Frederick, Maryland, USA.Ā 
  • 1996. PhD (Experimental Medicine), University of Rome “La Sapienza”.
  • 1996-2000. Research Scientist at the Laboratory of Immunology (Dept. Experimental Medicine and Pathology) and Laboratory of Pathophysiology, CRS, Regina Elena, Rome.
  • 2000-2007. Researcher-Lecturer – General Pathology (Med-04), Dept. of Experimental Medicine and Pathology, University of Rome “La Sapienza”.
  • 2007-2021. Associate Professor – General Pathology (Med-04), Dept. of Molecular Medicine, University of Rome “La Sapienza”.
  • 2021. Full Professor – General Pathology (Med-04), Dept. of Molecular Medicine, University of Rome “La Sapienza”.

Scientific interests

Prof. Cippitelli research activity has been mainly conducted in the field of transcriptional regulation and tumor immunology, aimed at understanding the mechanisms underlying the regulation of genes involved in NK cell antitumor effector functions.

  • Member of the Italian Society of Immunology, Clinical Immunology and Allergology (S.I.I.C.A.)
  • Referee of different international journals such as: Journal of Immunology, European Journal of Immunology, Immunology letters, Haematologica, Molecular Pharmacology, International Journal of Medical Sciences, Oncotarget, Annals of Hematology, Carcinogenesis, Cancers, Cells, Molecular Cancer.
  • Lecturer in Immunology and Immunopathology, General Pathology (Faculty of Pharmacy and Medicine University of Rome – La Sapienza, Italy).
  • Supervisor of Graduate Students, PhD Students and Postdoctoral Fellows.

Contribution to Science

My research has primarily focused on transcriptional regulation and tumor immunology, aiming to elucidate the mechanisms governing gene regulation in antitumor effector functions. Over the past ten years, I have investigated the interactions between Natural Killer cells -cytotoxic lymphocytes of the innate immune system- and Multiple Myeloma cells, a malignancy affecting plasma cells, to develop more tailored and effective immunotherapies.

These studies have highlighted the relevance of several molecular pathways modulated by selected chemotherapy drugs, which enhance the expression of activating ligands that boost the anti-cancer activity of these cytotoxic lymphocytes. This research lays the foundation for the development of novel immunotherapeutic approaches in the fight against cancer.

5 Selected publications

  • Petillo S, Sproviero E, Loconte L, Cuollo L, Zingoni A, Molfetta R, Fionda C, Soriani A, Cerboni C, Petrucci MT, Fazio F, Paolini R, Santoni A, Cippitelli M.
    NEDD8-activating enzyme inhibition potentiates the anti-myeloma activity of natural killer cells.
    Cell Death Dis. 2023 Jul 17;14(7):438. doi: 10.1038/s41419-023-05949-z.
  • Petillo S, Capuano C, Molfetta R, Fionda C, Mekhloufi A, Pighi C, Antonangeli F, Zingoni A, Soriani A, Petrucci M.T., Galandrini R, Paolini R, Santoni A and Cippitelli M.
    Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition.
    Cell Death and Disease,Ā 2021, 12(9), 836
  • Abruzzese MP, Bilotta MT, Fionda C, Zingoni A, Soriani A, Petrucci MT, Ricciardi MR, Molfetta R, Paolini R, Santoni A,Ā Cippitelli M.
    The homeobox transcription factor MEIS2 is a regulator of cancer cell survival and IMiDs activity in Multiple Myeloma: modulation by Bromodomain and Extra-Terminal (BET) protein inhibitors.
    Cell Death Dis. 2019 Apr 11;10(4):324. doi: 10.1038/s41419-019-1562-9.
  • Abruzzese MP, Bilotta MT, Fionda C, Zingoni A, Soriani A, Vulpis E, Borrelli C, Zitti B, Petrucci MT, Ricciardi MR, Molfetta R, Paolini R, Santoni A, Cippitelli M.
    Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
    J Hematol Oncol. 2016 Dec 1;9(1):134. doi: 10.1186/s13045-016-0362-2.
  • Fionda C, Di Bona D, Kosta A, Stabile H, Santoni A,Ā Cippitelli M.
    The POU-Domain Transcription Factor Oct-6/POU3F1 as a Regulator of Cellular Response to Genotoxic Stress.
    Cancers (Basel). 2019 Jun 11;11(6):810. doi: 10.3390/cancers11060810.

On-going Grants

Project Title Funding source Amount (Euros) Period Role of the PI
Role of Nucleolar Stress Response in the anticancer activity of Natural Killer cells against Multiple Myeloma. Istituto Pasteur Italia - research projects. 40.000 2025-2026 Coordinator (30 % of time)
Strategies to boost NK cell responses against cancer by regulation of NK cell-activating ligands, death receptors and effector activity. Ministry of the University, PRIN 122.773 2023-2026 Coordinator (40 % of time)
RNA Polymerase I inhibition and activation of Nucleolar Stress Response in the anticancer activity of Natural Killer cells against Multiple Myeloma. Progetti di Ricerca Grandi Ateneo ā€“ Sapienza University of Rome, Italy 30.000 2023-2026 Coordinator (30 % of time)

Complete list of published work in MyBibliography:

http://www.ncbi.nlm.nih.gov/pubmed/?term=cippitelli+m

1: Cuollo L, Di Cristofano S, Sandomenico A, Iaccarino E, Oliver A, Zingoni A, Cippitelli M, Fionda C, Petillo S, Kosta A, Tassinari V, Petrucci MT, Fazio F, Ruvo M, Santoni A, Raimondo D, Soriani A. CD38 restrains the activity of extracellular cGAMP in a model of multiple myeloma. iScience. 2024 Apr

25;27(5):109814. doi: 10.1016/j.isci.2024.109814. PMID: 38746669; PMCID: PMC11091702.

2: Zingoni A, Antonangeli F, Sozzani S, Santoni A, Cippitelli M, Soriani A. The senescence journey in cancer immunoediting. Mol Cancer. 2024 Apr 1;23(1):68. doi: 10.1186/s12943-024-01973-5. PMID: 38561826; PMCID: PMC10983694.

3: Petillo S, Sproviero E, Loconte L, Cuollo L, Zingoni A, Molfetta R, Fionda C, Soriani A, Cerboni C, Petrucci MT, Fazio F, Paolini R, Santoni A, Cippitelli M. NEDD8-activating enzyme inhibition potentiates the anti-myeloma activity of natural killer cells. Cell Death Dis. 2023 Jul 17;14(7):438. doi: 10.1038/s41419-023-05949-z. PMID: 37460534; PMCID: PMC10352239.

4: Molfetta R, Petillo S, Cippitelli M, Paolini R. SUMOylation and related post-translational modifications in natural killer cell anti-cancer responses. Front Cell Dev Biol. 2023 May 25;11:1213114. doi: 10.3389/fcell.2023.1213114. PMID: 37313439; PMCID: PMC10258607.

5: Vulpis E, Loconte L, Cassone C, Antonangeli F, Caracciolo G, Masuelli L, Fazio F, Petrucci MT, Fionda C, Soriani A, Cerboni C, Cippitelli M, Santoni A,

Zingoni A. Cross-Dressing of Multiple Myeloma Cells Mediated by Extracellular Vesicles Conveying MIC and ULBP Ligands Promotes NK Cell Killing. Int J Mol Sci. 2023 May 30;24(11):9467. doi: 10.3390/ijms24119467. PMID: 37298418; PMCID: PMC10253317.

6: Vulpis E, Cuollo L, Borrelli C, Antonangeli F, Masuelli L, Cippitelli M, Fionda C, Caracciolo G, Petrucci MT, Santoni A, Zingoni A, Soriani A.

Doxorubicin-Mediated miR-433 Expression on Exosomes Promotes Bystander Senescence in Multiple Myeloma Cells in a DDR-Independent Manner. Int J Mol Sci. 2023 Apr 6;24(7):6862. doi: 10.3390/ijms24076862. PMID: 37047835; PMCID: PMC10095495.

7: Cippitelli M, Stabile H, Kosta A, Petillo S, Lucantonio L, Gismondi A, Santoni A, Fionda C. Role of NF-ƎĀŗB Signaling in the Interplay between Multiple Myeloma and Mesenchymal Stromal Cells. Int J Mol Sci. 2023 Jan 17;24(3):1823. doi: 10.3390/ijms24031823. PMID: 36768145; PMCID: PMC9916119.

8: Milito ND, Zingoni A, Stabile H, Soriani A, Capuano C, Cippitelli M, Gismondi A, Santoni A, Paolini R, Molfetta R. NKG2D engagement on human NK cells leads to DNAM-1 hypo-responsiveness through different converging mechanisms. Eur J Immunol. 2023 Feb;53(2):e2250198. doi: 10.1002/eji.202250198. Epub 2022 Dec 8. PMID: 36440686.

9: Kosta A, Mekhloufi A, Lucantonio L, Zingoni A, Soriani A, Cippitelli M, Gismondi A, Fazio F, Petrucci MT, Santoni A, Stabile H, Fionda C. GAS6/TAM

signaling pathway controls MICA expression in multiple myeloma cells. Front Immunol. 2022 Jul 28;13:942640. doi: 10.3389/fimmu.2022.942640. PMID: 35967396; PMCID: PMC9368199.

10: Vulpis E, Loconte L, Peri A, Molfetta R, Caracciolo G, Masuelli L, Tomaipitinca L, Peruzzi G, Petillo S, Petrucci MT, Fazio F, Simonelli L, Fionda

C, Soriani A, Cerboni C, Cippitelli M, Paolini R, Bernardini G, Palmieri G, Santoni A, Zingoni A. Impact on NK cell functions of acute versus chronic

exposure to extracellular vesicle-associated MICA: Dual role in cancer immunosurveillance. J Extracell Vesicles. 2022 Jan;11(1):e12176. doi:

10.1002/jev2.12176. PMID: 34973063; PMCID: PMC8720178.

11: Petillo S, Capuano C, Molfetta R, Fionda C, Mekhloufi A, Pighi C, Antonangeli F, Zingoni A, Soriani A, Petrucci MT, Galandrini R, Paolini R,

Santoni A, Cippitelli M. Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition. Cell Death Dis. 2021 Sep 4;12(9):836. doi: 10.1038/s41419-021-04104-w. PMID: 34482362; PMCID: PMC8418610.

12: Fionda C, Stabile H, Molfetta R, Kosta A, Peruzzi G, Ruggeri S, Zingoni A, Capuano C, Soriani A, Paolini R, Gismondi A, Cippitelli M, Santoni A. Cereblon regulates NK cell cytotoxicity and migration via Rac1 activation. Eur J Immunol. 2021 Nov;51(11):2607-2617. doi: 10.1002/eji.202149269. Epub 2021 Sep 18. PMID: 34392531; PMCID: PMC9291148.

13: Cippitelli M, Stabile H, Kosta A, Petillo S, Gismondi A, Santoni A, Fionda Role of Aiolos and Ikaros in the Antitumor and Immunomodulatory Activity of IMiDs in Multiple Myeloma: Better to Lose Than to Find Them. Int J Mol Sci. 2021 Jan 22;22(3):1103. doi: 10.3390/ijms22031103. PMID: 33499314; PMCID: PMC7865245.

14: Bilotta MT, Petillo S, Santoni A, Cippitelli M. Liver X Receptors: Regulators of Cholesterol Metabolism, Inflammation, Autoimmunity, and Cancer.

Front Immunol. 2020 Nov 3;11:584303. doi: 10.3389/fimmu.2020.584303. PMID: 33224146; PMCID: PMC7670053.

15: Mekhloufi A, Kosta A, Stabile H, Molfetta R, Zingoni A, Soriani A, Cippitelli M, Paolini R, Gismondi A, Ricciardi MR, Petrucci MT, Masuelli L,

Caracciolo G, Palchetti S, Santoni A, Fionda C. Bone Marrow Stromal Cell-Derived IL-8 Upregulates PVR Expression on Multiple Myeloma Cells via NF-kB Transcription Factor. Cancers (Basel). 2020 Feb 13;12(2):440. doi: 10.3390/cancers12020440. PMID: 32069911; PMCID: PMC7072437.

16: Molfetta R, Zitti B, Lecce M, Milito ND, Stabile H, Fionda C, Cippitelli M, Gismondi A, Santoni A, Paolini R. CD155: A Multi-Functional Molecule in Tumor Progression. Int J Mol Sci. 2020 Jan 30;21(3):922. doi: 10.3390/ijms21030922. PMID: 32019260; PMCID: PMC7037299.

17: Fionda C, Stabile H, Cerboni C, Soriani A, Gismondi A, Cippitelli M, Santoni Hitting More Birds with a Stone: Impact of TGF-ƎĀ² on ILC Activity in Cancer. J Clin Med. 2020 Jan 5;9(1):143. doi: 10.3390/jcm9010143. PMID: 31948072; PMCID: PMC7019362.

18: Acquati F, Mortara L, De Vito A, Baci D, Albini A, Cippitelli M, Taramelli R, Noonan DM. Innate Immune Response Regulation by the Human RNASET2 Tumor Suppressor Gene. Front Immunol. 2019 Nov 5;10:2587. doi: 10.3389/fimmu.2019.02587. PMID: 31749812; PMCID: PMC6848152.

19: Fionda C, Di Bona D, Kosta A, Stabile H, Santoni A, Cippitelli M. The POU-Domain Transcription Factor Oct-6/POU3F1 as a Regulator of Cellular Response to Genotoxic Stress. Cancers (Basel). 2019 Jun 11;11(6):810. doi: 10.3390/cancers11060810. PMID: 31212703; PMCID: PMC6627474.

20: Bilotta MT, Abruzzese MP, Molfetta R, Scarno G, Fionda C, Zingoni A, Soriani A, Garofalo T, Petrucci MT, Ricciardi MR, Paolini R, Santoni A, Cippitelli M. Activation of liver X receptor up-regulates the expression of the NKG2D ligands MICA and MICB in multiple myeloma through different molecular mechanisms. FASEB 2019 Aug;33(8):9489-9504. doi: 10.1096/fj.201900319R. Epub 2019 May 24. PMID: 31125275.

21: Abruzzese MP, Bilotta MT, Fionda C, Zingoni A, Soriani A, Petrucci MT, Ricciardi MR, Molfetta R, Paolini R, Santoni A, Cippitelli M. The homeobox

transcription factor MEIS2 is a regulator of cancer cell survival and IMiDs activity in Multiple Myeloma: modulation by Bromodomain and Extra-Terminal (BET) protein inhibitors. Cell Death Dis. 2019 Apr 11;10(4):324. doi: 10.1038/s41419-019-1562-9. PMID: 30975979; PMCID: PMC6459881.

22: Molfetta R, Milito ND, Zitti B, Lecce M, Fionda C, Cippitelli M, Santoni A, Paolini R. The Ubiquitin-proteasome pathway regulates Nectin2/CD112 expression and impairs NK cell recognition and killing. Eur J Immunol. 2019 Jun;49(6):873-883. doi: 10.1002/eji.201847848. Epub 2019 Mar 27. PMID: 30888046.

23: Vulpis E, Stabile H, Soriani A, Fionda C, Petrucci MT, Mariggio’ E, Ricciardi MR, Cippitelli M, Gismondi A, Santoni A, Zingoni A. Key Role of the

CD56lowCD16low Natural Killer Cell Subset in the Recognition and Killing of Multiple Myeloma Cells. Cancers (Basel). 2018 Nov 29;10(12):473. doi: 10.3390/cancers10120473. PMID: 30501078; PMCID: PMC6317053.

24: Fionda C, Stabile H, Molfetta R, Soriani A, Bernardini G, Zingoni A, Gismondi A, Paolini R, Cippitelli M, Santoni A. Translating the anti-myeloma

activity of Natural Killer cells into clinical application. Cancer Treat Rev. 2018 Nov;70:255-264. doi: 10.1016/j.ctrv.2018.10.005. Epub 2018 Oct 10. PMID: 30326421.

25: Zingoni A, Vulpis E, Cecere F, Amendola MG, Fuerst D, Saribekyan T, Achour A, Sandalova T, Nardone I, Peri A, Soriani A, Fionda C, MariggiƃĀ² E, Petrucci MT, Ricciardi MR, Mytilineos J, Cippitelli M, Cerboni C, Santoni A. MICA-129 Dimorphism and Soluble MICA Are Associated With the Progression of Multiple Myeloma. Front Immunol. 2018 May 1;9:926. doi: 10.3389/fimmu.2018.00926. PMID: 29765374; PMCID: PMC5938351.

26: Borrelli C, Ricci B, Vulpis E, Fionda C, Ricciardi MR, Petrucci MT, Masuelli L, Peri A, Cippitelli M, Zingoni A, Santoni A, Soriani A. Drug-Induced Senescent Multiple Myeloma Cells Elicit NK Cell Proliferation by Direct or Exosome- Mediated IL15 Trans-Presentation. Cancer Immunol Res. 2018 Jul;6(7):860-869. doi: 10.1158/2326-6066.CIR-17-0604. Epub 2018 Apr 24. PMID: 29691234.

27: Zingoni A, Molfetta R, Fionda C, Soriani A, Paolini R, Cippitelli M, Cerboni C, Santoni A. NKG2D and Its Ligands: “One for All, All for One”. Front Immunol. 2018 Mar 12;9:476. doi: 10.3389/fimmu.2018.00476. PMID: 29662484; PMCID: PMC5890157.

28: Zingoni A, Fionda C, Borrelli C, Cippitelli M, Santoni A, Soriani A. Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance. Front Immunol. 2017 Sep 25;8:1194. doi: 10.3389/fimmu.2017.01194. PMID: 28993779; PMCID: PMC5622151.

29: Zitti B, Molfetta R, Fionda C, Quatrini L, Stabile H, Lecce M, de Turris V, Ricciardi MR, Petrucci MT, Cippitelli M, Gismondi A, Santoni A, Paolini R. Innate immune activating ligand SUMOylation affects tumor cell recognition by NK cells. Sci Rep. 2017 Sep 5;7(1):10445. doi: 10.1038/s41598-017-10403-0. PMID: 28874810; PMCID: PMC5585267.

30: Vulpis E, Cecere F, Molfetta R, Soriani A, Fionda C, Peruzzi G, Caracciolo G, Palchetti S, Masuelli L, Simonelli L, D’Oro U, Abruzzese MP, Petrucci MT, Ricciardi MR, Paolini R, Cippitelli M, Santoni A, Zingoni A. Genotoxic stress modulates the release of exosomes from multiple myeloma cells capable of activating NK cell cytokine production: Role of HSP70/TLR2/NF-kB axis. Oncoimmunology. 2017 Jan 13;6(3):e1279372. doi: 10.1080/2162402X.2017.1279372. PMID: 28405503; PMCID: PMC5384384.

31: Soriani A, Borrelli C, Ricci B, Molfetta R, Zingoni A, Fionda C, Carnevale S, Abruzzese MP, Petrucci MT, Ricciardi MR, La Regina G, Di Cesare E, Lavia P, Silvestri R, Paolini R, Cippitelli M, Santoni A. p38 MAPK differentially controls NK activating ligands at transcriptional and post-transcriptional level on multiple myeloma cells. Oncoimmunology. 2016 Dec 2;6(1):e1264564. doi: 10.1080/2162402X.2016.1264564. PMID: 28197392; PMCID: PMC5283620.

32: Abruzzese MP, Bilotta MT, Fionda C, Zingoni A, Soriani A, Vulpis E, Borrelli C, Zitti B, Petrucci MT, Ricciardi MR, Molfetta R, Paolini R, Santoni A, Cippitelli M. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated

cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay. J Hematol Oncol. 2016 Dec 1;9(1):134. doi: 10.1186/s13045-016-0362-2. PMID: 27903272; PMCID: PMC5131470.

33: Fionda C, Abruzzese MP, Santoni A, Cippitelli M. Immunoregulatory and Effector Activities of Nitric Oxide and Reactive Nitrogen Species in Cancer. Curr Med Chem. 2016;23(24):2618-2636. doi: 10.2174/0929867323666160727105101. PMID: 27464520.

34: Pignoloni B, Fionda C, Dell’Oste V, Luganini A, Cippitelli M, Zingoni A, Landolfo S, Gribaudo G, Santoni A, Cerboni C. Distinct Roles for Human Cytomegalovirus Immediate Early Proteins IE1 and IE2 in the Transcriptional Regulation of MICA and PVR/CD155 Expression. J Immunol. 2016 Nov 15;197(10):4066-4078. doi: 10.4049/jimmunol.1502527. Epub 2016 Oct 12. PMID: 27733551.

35: Zingoni A, Vulpis E, Nardone I, Soriani A, Fionda C, Cippitelli M, Santoni

  1. Targeting NKG2D and NKp30 Ligands Shedding to Improve NK Cell-Based

Immunotherapy. Crit Rev Immunol. 2016;36(6):445-460. doi: 10.1615/CritRevImmunol.2017020166. PMID: 28845754.

36: Quatrini L, Molfetta R, Zitti B, Peruzzi G, Fionda C, Capuano C, Galandrini R, Cippitelli M, Santoni A, Paolini R. Ubiquitin-dependent endocytosis of NKG2D-DAP10 receptor complexes activates signaling and functions in human NK cells. Sci Signal. 2015 Oct 27;8(400):ra108. doi: 10.1126/scisignal.aab2724. PMID: 26508790.

37: Fionda C, Abruzzese MP, Zingoni A, Cecere F, Vulpis E, Peruzzi G, Soriani A, Molfetta R, Paolini R, Ricciardi MR, Petrucci MT, Santoni A, Cippitelli M. The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell- activating ligands expression in multiple myeloma. Oncotarget. 2015 Sep 15;6(27):23609-30. doi: 10.18632/oncotarget.4603. PMID: 26269456; PMCID: PMC4695140.

38: Fionda C, Soriani A, Zingoni A, Santoni A, Cippitelli M. NKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple Myeloma. Biomed Res Int. 2015;2015:178698. doi: 10.1155/2015/178698. Epub 2015 Jun 16. PMID: 26161387; PMCID: PMC4486747.

39: Zingoni A, Cecere F, Vulpis E, Fionda C, Molfetta R, Soriani A, Petrucci MT, Ricciardi MR, Fuerst D, Amendola MG, Mytilineos J, Cerboni C, Paolini R, Cippitelli M, Santoni A. Genotoxic Stress Induces Senescence-Associated ADAM10-Dependent Release of NKG2D MIC Ligands in Multiple Myeloma Cells. J Immunol. 2015 Jul 15;195(2):736-48. doi: 10.4049/jimmunol.1402643. Epub 2015 Jun 12. PMID: 26071561.

40: Fionda C, Abruzzese MP, Zingoni A, Soriani A, Ricci B, Molfetta R, Paolini R, Santoni A, Cippitelli M. Nitric oxide donors increase PVR/CD155 DNAM-1 ligand expression in multiple myeloma cells: role of DNA damage response activation. BMC Cancer. 2015 Jan 22;15:17. doi: 10.1186/s12885-015-1023-5. PMID: 25609078; PMCID: PMC4311457.

41: Soriani A, Iannitto ML, Ricci B, Fionda C, Malgarini G, Morrone S, Peruzzi G, Ricciardi MR, Petrucci MT, Cippitelli M, Santoni A. Reactive oxygen species- and DNA damage response-dependent NK cell activating ligand upregulation occurs at transcriptional levels and requires the transcriptional factor E2F1. JImmunol. 2014 Jul 15;193(2):950-60. doi: 10.4049/jimmunol.1400271. Epub 2014 Jun 9. PMID: 24913980.

42: Di Bona D, Scafidi V, Plaia A, Colomba C, Nuzzo D, Occhino C, Tuttolomondo A, Giammanco G, De Grazia S, Montalto G, Duro G, Cippitelli M, Caruso C. HLA and killer cell immunoglobulin-like receptors influence the natural course of CMV infection. J Infect Dis. 2014 Oct 1;210(7):1083-9. doi: 10.1093/infdis/jiu226. Epub 2014 Apr 15. PMID: 24737799.

43: Soriani A, Fionda C, Ricci B, Iannitto ML, Cippitelli M, Santoni A. Chemotherapy-elicited upregulation of NKG2D and DNAM-1 ligands as a therapeutic target in multiple myeloma. Oncoimmunology. 2013 Dec 1;2(12):e26663. doi: 10.4161/onci.26663. Epub 2013 Oct 22. PMID: 24498552; PMCID: PMC3912005.

44: Cerboni C, Fionda C, Soriani A, Zingoni A, Doria M, Cippitelli M, Santoni A. The DNA Damage Response: A Common Pathway in the Regulation of NKG2D and DNAM-1 Ligand Expression in Normal, Infected, and Cancer Cells. Front Immunol. 2014 Jan 7;4:508. doi: 10.3389/fimmu.2013.00508. PMID: 24432022; PMCID: PMC3882864.

45: Fionda C, Malgarini G, Soriani A, Zingoni A, Cecere F, Iannitto ML, Ricciardi MR, Federico V, Petrucci MT, Santoni A, Cippitelli M. Inhibition of glycogen synthase kinase-3 increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of STAT3. J Immunol. 2013 Jun 15;190(12):6662-72. doi: 10.4049/jimmunol.1201426. Epub 2013 May 17. PMID: 23686482.

46: Quinci AC, Vitale S, Parretta E, Soriani A, Iannitto ML, Cippitelli M, Fionda C, Bulfone-Paus S, Santoni A, Di Rosa F. IL-15 inhibits IL-7RƎĀ± expression by memory-phenotype CD8Ć¢ĀĀŗ T cells in the bone marrow. Eur J Immunol. 2012 May;42(5):1129-39. doi: 10.1002/eji.201142019. PMID: 22539288.

47: Fionda C, Soriani A, Malgarini G, Iannitto ML, Santoni A, Cippitelli M. Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation. J Immunol. 2009 Oct 1;183(7):4385-94. doi: 10.4049/jimmunol.0901797. Epub 2009 Sep 11. PMID: 19748980.

48: Nappi F, Chiozzini C, Bordignon V, Borsetti A, Bellino S, Cippitelli M, Barillari G, Caputo A, Tyagi M, Giacca M, Ensoli B. Immobilized HIV-1 Tat protein promotes gene transfer via a transactivation-independent mechanism which requires binding of Tat to viral particles. J Gene Med. 2009 Nov;11(11):955-65. doi: 10.1002/jgm.1381. PMID: 19653251.

49: Soriani A, Zingoni A, Cerboni C, Iannitto ML, Ricciardi MR, Di Gialleonardo V, Cippitelli M, Fionda C, Petrucci MT, Guarini A, FoƃĀ  R, Santoni A. ATM-ATR- dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood. 2009 Apr 9;113(15):3503-11. doi: 10.1182/blood-2008-08-173914. Epub 2008 Dec 19. PMID: 19098271.

50: Fionda C, Nappi F, Piccoli M, Frati L, Santoni A, Cippitelli M. Inhibition of trail gene expression by cyclopentenonic prostaglandin 15-deoxy- delta12,14-prostaglandin J2 in T lymphocytes. Mol Pharmacol. 2007 Nov;72(5):1246-57. doi: 10.1124/mol.107.038042. Epub 2007 Aug 2. PMID: 17673570.

51: Cerboni C, Zingoni A, Cippitelli M, Piccoli M, Frati L, Santoni A. Antigen- activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR- dependent mechanism and become susceptible to autologous NK- cell lysis. Blood. 2007 Jul 15;110(2):606-15. doi: 10.1182/blood-2006-10-052720. Epub 2007 Apr 3. PMID: 17405908.

52: Fionda C, Nappi F, Piccoli M, Frati L, Santoni A, Cippitelli M. 15-deoxy- Delta12,14-prostaglandin J2 negatively regulates rankl gene expression in activated T lymphocytes: role of NF-kappaB and early growth response transcription factors. J Immunol. 2007 Apr 1;178(7):4039-50. doi: 10.4049/jimmunol.178.7.4039. PMID: 17371958.

53: Di Bona D, Cippitelli M, Fionda C, CammƃĀ  C, Licata A, Santoni A, CraxƃĀ¬ A. Oxidative stress inhibits IFN-alpha-induced antiviral gene expression by blocking the JAK-STAT pathway. J Hepatol. 2006 Aug;45(2):271-9. doi: 10.1016/j.jhep.2006.01.037. Epub 2006 Mar 9. PMID: 16595158.

54: Cippitelli M, Fionda C, Di Bona D, Piccoli M, Frati L, Santoni A. Hyperthermia enhances CD95-ligand gene expression in T lymphocytes. J Immunol. 2005 Jan 1;174(1):223-32. doi: 10.4049/jimmunol.174.1.223. PMID: 15611244.

55: Cippitelli M, Fionda C, Di Bona D, Lupo A, Piccoli M, Frati L, Santoni A. The cyclopentenone-type prostaglandin 15-deoxy-delta 12,14-prostaglandin J2 inhibits CD95 ligand gene expression in T lymphocytes: interference with promoter activation via peroxisome proliferator-activated receptor-gamma- independent mechanisms. J Immunol. 2003 May 1;170(9):4578-92. doi: 10.4049/jimmunol.170.9.4578. PMID: 12707336.

56: Cippitelli M, Fionda C, Di Bona D, Di Rosa F, Lupo A, Piccoli M, Frati L, Santoni A. Negative regulation of CD95 ligand gene expression by vitamin D3 in T lymphocytes. J Immunol. 2002 Feb 1;168(3):1154-66. doi: 10.4049/jimmunol.168.3.1154. PMID: 11801650.

57: Ricca A, Biroccio A, Trisciuoglio D, Cippitelli M, Zupi G, Del Bufalo D. relA over-expression reduces tumorigenicity and activates apoptosis in human cancer cells. Br J Cancer. 2001 Dec 14;85(12):1914-21. doi: 10.1054/bjoc.2001.2174. PMID: 11747334; PMCID: PMC2364001.

58: Ricca A, Biroccio A, Del Bufalo D, Mackay AR, Santoni A, Cippitelli M. bcl-2 over-expression enhances NF-kappaB activity and induces mmp-9 transcription in human MCF7(ADR) breast-cancer cells. Int J Cancer. 2000 Apr 15;86(2):188-96. doi: 10.1002/(sici)1097-0215(20000415)86:2<188::aid-ijc7>3.0.co;2-w. PMID: 10738245.

59: Cippitelli M, Santoni A. Vitamin D3: a transcriptional modulator of the interferon-gamma gene. Eur J Immunol. 1998 Oct;28(10):3017-30. doi: 10.1002/(SICI)1521-4141(199810)28:10<3017::AID-IMMU3017>3.0.CO;2-6. PMID: 9808170.

60: Mainiero F, Gismondi A, Soriani A, Cippitelli M, Palmieri G, Jacobelli J, Piccoli M, Frati L, Santoni A. Integrin-mediated ras-extracellular regulated kinase (ERK) signaling regulates interferon gamma production in human natural killer cells. J Exp Med. 1998 Oct 5;188(7):1267-75. doi: 10.1084/jem.188.7.1267. PMID: 9763606; PMCID: PMC2212502.

61: D’Ambrosio D, Cippitelli M, Cocciolo MG, Mazzeo D, Di Lucia P, Lang R, Sinigaglia F, Panina-Bordignon P. Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. J Clin Invest. 1998 Jan 1;101(1):252-62. doi: 10.1172/JCI1050. PMID: 9421488; PMCID: PMC508562.

62: Sica A, Dorman L, Viggiano V, Cippitelli M, Ghosh P, Rice N, Young HA. Interaction of NF-kappaB and NFAT with the interferon-gamma promoter. J Biol Chem. 1997 Nov 28;272(48):30412-20. doi: 10.1074/jbc.272.48.30412. PMID: 9374532.

63: Curiel RE, Lahesmaa R, Subleski J, Cippitelli M, Kirken RA, Young HA, Ghosh

  1. Identification of a Stat-6-responsive element in the promoter of the human interleukin-4 gene. Eur J Immunol. 1997 Aug;27(8):1982-7. doi: 10.1002/eji.1830270823. PMID: 9295035.

64: Cippitelli M, Ye J, Viggiano V, Sica A, Ghosh P, Gulino A, Santoni A, Young

  1. Retinoic acid-induced transcriptional modulation of the human interferon- gamma promoter. J Biol Chem. 1996 Oct 25;271(43):26783-93. doi: 10.1074/jbc.271.43.26783. PMID: 8900159.

65: Ye J, Cippitelli M, Dorman L, Ortaldo JR, Young HA. The nuclear factor YY1 suppresses the human gamma interferon promoter through two mechanisms: inhibition of AP1 binding and activation of a silencer element. Mol Cell Biol. 1996 Sep;16(9):4744-53. doi: 10.1128/MCB.16.9.4744. PMID: 8756632; PMCID: PMC231475.

66: Ghosh P, Sica A, Cippitelli M, Subleski J, Lahesmaa R, Young HA, Rice NR. Activation of nuclear factor of activated T cells in a cyclosporin A-resistant pathway. J Biol Chem. 1996 Mar 29;271(13):7700-4. doi: 10.1074/jbc.271.13.7700. PMID: 8631809.

67: Ghosh P, Komschlies KL, Cippitelli M, Longo DL, Subleski J, Ye J, Sica A, Young HA, Wiltrout RH, Ochoa AC. Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor growth. J Natl Cancer Inst. 1995 Oct 4;87(19):1478-83. doi: 10.1093/jnci/87.19.1478. PMID: 7674335.

68: Cippitelli M, Sica A, Viggiano V, Ye J, Ghosh P, Birrer MJ, Young HA. Negative transcriptional regulation of the interferon-gamma promoter by glucocorticoids and dominant negative mutants of c-Jun. J Biol Chem. 1995 May 26;270(21):12548-56. doi: 10.1074/jbc.270.21.12548. PMID: 7759501.

69: Ye J, Ghosh P, Cippitelli M, Subleski J, Hardy KJ, Ortaldo JR, Young HA. Characterization of a silencer regulatory element in the human interferon-gamma promoter. J Biol Chem. 1994 Oct 14;269(41):25728-34. PMID: 7929277.

70: Velotti F, Giuffrida A, Cippitelli M, Stoppacciaro A, Tubaro A, Ruco L, Santoni A. Soluble and cell-associated IL-2 receptor (IL-2R) after local immunotherapy with recombinant interleukin-2 (rIL-2). Pharmacol Res. 1992 Sep;26

Suppl 2:52-3. doi: 10.1016/1043-6618(92)90595-3.

Ā 

Ā 

KEYWORDS:

Myeloma, Innate Immunity, Immunotherapy, Natural Killer, Transcription, Chemotherapy.

↑